4-[(2-苯乙基)氨基]-6-喹唑啉甲腈 | 1366002-50-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-[(2-苯乙基)氨基]-6-喹唑啉甲腈
• 中文别名: 4-(苯乙基氨基)喹唑啉-6-甲腈；CDK8抑制剂(SENEXINA)
• 英文名称: 4-(Phenethylamino)quinazoline-6-carbonitrile
• 英文别名: 4-(2-phenylethylamino)quinazoline-6-carbonitrile
• CAS: 1366002-50-7
• 化学式: C₁₇H₁₄N₄
• 分子量: 274.32
• InChiKey: XBJCNHGQFJFCOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• METHODS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER
  申请人：Chan Zuckerberg Biohub, Inc.

  公开号：EP3684420A1

  公开（公告）日：2020-07-29
• TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
  申请人：Roninson Igor B.

  公开号：US20140309224A1

  公开（公告）日：2014-10-16

  The invention provides a method for treating a disease or disorder in a mammal which is caused by induced NFkB transcriptional activity in cells of the mammal, the method comprising administering to the mammal a compound that specifically inhibits one or more of CDK8 and CDK19.
• COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS
  申请人：LU LICENSE AB

  公开号：US20190111034A1

  公开（公告）日：2019-04-18

  The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.
• METHOD FOR EFFICIENT GENERATION OF NEURONS FROM NON-NEURONAL CELLS
  申请人：Massachusetts Institute of Technology

  公开号：US20200123499A1

  公开（公告）日：2020-04-23

  This disclosure provides, in part, methods and compositions relating to the genetic reprogramming of non-neuronal cells into neuronal cells. The disclosure further methods and compositions relating to reprogramming neural cells away from the neural fate.
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210238226A1

  公开（公告）日：2021-08-05

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.